HF
ZNTL icon

HRT Financial’s Zentalis Pharmaceuticals ZNTL Stock Holding History

HRT Financial’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
+52,185
New +$135K ﹤0.01% 3312
2025
Q4 		– Sell
-30,424
Closed -$45K – 4190
2025
Q3 		$45K Sell
30,424
-83,439
-73% -$125K ﹤0.01% 2617
2025
Q2 		$132K Buy
+113,863
New +$150K ﹤0.01% 2157
2025
Q1 		– Sell
-140,394
Closed -$425K – 3526
2024
Q4 		$425K Buy
140,394
+61,467
+78% +$201K ﹤0.01% 1539
2024
Q3 		$290K Buy
+78,927
New +$287K ﹤0.01% 1819
2024
Q2 		– Sell
-113,750
Closed -$1.79M – 3249
2024
Q1 		$1.79M Buy
+113,750
New +$1.56M 0.01% 620

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

HRT Financial's ZNTL Position: Q1 2026 in Review

HRT Financial opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q1 2026: 52,185 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #3312 among its holdings. This is a return to the name: HRT Financial previously reported a position in ZNTL as recently as Q3 2025.

HRT Financial first reported a position in ZNTL in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.79M in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • HRT Financial held 52,185 shares of Zentalis Pharmaceuticals worth $122K as of Q1 2026.
  • Zentalis Pharmaceuticals was a new HRT Financial position in Q1 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3312 holding.
  • HRT Financial first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • HRT Financial's Zentalis Pharmaceuticals position peaked at $1.79M in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.